125 related articles for article (PubMed ID: 17631996)
1. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma.
Olver IN; Byrne MJ; Walpole E; Vorobiof D; Jacobs C; Maart K; Hewitt S; McAdam G; Pouget JC; Pinel MC
Eur J Cancer; 2007 Aug; 43(12):1829-32. PubMed ID: 17631996
[TBL] [Abstract][Full Text] [Related]
2. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
3. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Morawek L; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
5. Vindesine for metastatic malignant melanoma. A phase II trial.
Nelimark RA; Peterson BA; Vosika GJ; Conroy JA
Am J Clin Oncol; 1983 Oct; 6(5):561-4. PubMed ID: 6613921
[TBL] [Abstract][Full Text] [Related]
6. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK; Radny P; Hauschild A; Gutzmer R; Linse R; Pföhler C; Wagner SN; Schadendorf D; Ellwanger U; Garbe C;
Melanoma Res; 2008 Oct; 18(5):353-8. PubMed ID: 18781134
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma.
Feun LG; Savaraj N; Hurley J; Marini A; Lai S
Cancer; 2000 Feb; 88(3):584-8. PubMed ID: 10649251
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
[TBL] [Abstract][Full Text] [Related]
13. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
Martín-Algarra S; Espinosa E; Rubió J; López López JJ; Manzano JL; Carrión LA; Plazaola A; Tanovic A; Paz-Ares L
Eur J Cancer; 2009 Mar; 45(5):732-5. PubMed ID: 19186051
[TBL] [Abstract][Full Text] [Related]
15. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.
Blasinska-Morawiec M; Tubiana-Mathieu N; Fougeray R; Pinel MC; Bougnoux P
Breast; 2013 Feb; 22(1):58-63. PubMed ID: 23195794
[TBL] [Abstract][Full Text] [Related]
17. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the combination of vinblastine plus cisplatin administered by continuous 120-hour infusion for patients with advanced malignant melanoma.
Creagan ET; Ahmann DL; Schutt AJ; Schaid DJ
Cancer Treat Rep; 1987; 71(7-8):769-70. PubMed ID: 3607788
[No Abstract] [Full Text] [Related]
19. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
